Darryl Prime, MD
Interventional Cardiology · Birmingham, ALNPI 1982668828
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,250 of the $14,746 with a category attached, or 76.3%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 76.7% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2021 at $6,083 and has fallen 89.4% since, to $647 in 2025.
Across 118 payments — averaging $124.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$11K
- ZOLL Circulation Inc$406
- Abiomed$406
- Abbott$329
- Philips North America LLC$287
- Novartis$271
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$11,25076%
- Travel & lodging$1691%
- Food & beverage$3,32723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $11,308 |
| ZOLL Circulation Inc | 4 | $406 |
| Abiomed | 6 | $406 |
| Abbott | 18 | $329 |
| Philips North America LLC | 6 | $287 |
| Novartis | 17 | $271 |
| Medtronic | 3 | $218 |
| Penumbra, Inc. | 2 | $215 |
| Cardiovascular Systems Inc. | 3 | $199 |
| Johnson & Johnson | 11 | $188 |
| Inari Medical, Inc. | 1 | $179 |
| Boston Scientific | 2 | $160 |
| Angiodynamics, Inc. | 3 | $144 |
| Pfizer | 5 | $98 |
| Amgen | 4 | $59 |
| Janssen Scientific Affairs, LLC | 1 | $42 |
| Chiesi USA, Inc. | 2 | $41 |
| Teleflex LLC | 1 | $33 |
| Terumo Medical Corporation | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Shockwave Medical, Inc | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| AstraZeneca | 1 | $16 |
| Merck | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$11,250
- TherOx DS2 Console$269
- Catheter$269
- Downstream Cartridge$269
- Impella$257
- FLOWTRIEVER CATHETER, S$179
- CT THROMBECTOMY SYSTEM KIT$179
- Diamondback Peripheral$169
- COREVALVE EVOLUT R$167
- Indigo System$115
- Penumbra System$100
How this compares
$14,746 in reported general payments places this provider in the 75th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 32 | $20,299 |
| EntrestoSacubitril/Valsartan | 17 | $17,727 |
| XareltoRivaroxaban | 22 | $16,364 |
| EliquisApixaban | 21 | $14,122 |
| JardianceEmpagliflozin | 16 | $13,743 |
| Potassium Chloride | 23 | $2,158 |
| Ranolazine ErRanolazine | 11 | $1,570 |
| Metoprolol Succinate | 54 | $842 |
| Rosuvastatin Calcium | 19 | $668 |
| Atorvastatin Calcium | 24 | $594 |
| ClopidogrelClopidogrel Bisulfate | 32 | $422 |
| Amlodipine Besylate | 39 | $388 |
| Carvedilol | 28 | $322 |
| Losartan Potassium | 19 | $194 |
| Furosemide | 33 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $271 | $17,72717 claims |
| Johnson & JohnsonXarelto | $188 | $16,36422 claims |
| PfizerEliquis | $98 | $14,12221 claims |
| Boehringer IngelheimJardiance | $21 | $13,74316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Birmingham
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- Abdullah MahmoodBirmingham$61K
- Ali EbrahimiBirmingham$55K
- Jacob TownsendBirmingham$52K
- Kamran AliBirmingham$47K
- Mouhamed SabouniBirmingham$44K
- David SchultzBirmingham$19K
- Tushar MishraBirmingham$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.